European equities traded in the US as American depositary receipts were trending modestly lower late Friday morning, down 0.23% to 1,399.64 on the S&P Europe Select ADR Index. Despite the decline, the ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Ascendis Pharma (ASND – Research Report), with a ...

Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report) today and set a price target ...

Cantor Fitzgerald upgraded shares of Beam Therapeutics (NASDAQ:BEAM – Free Report) from a neutral rating to an overweight rating in a research note published on Wednesday morning, Marketbeat reports.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Here we highlight a subset of our preferred stocks from the screener. Overview: GDS Holdings Limited, along with its subsidiaries, specializes in the development and operation of data centers across ...

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against other high growth international stocks to invest in now. On January 15, Jurrien Timmer ...